Amid a yearslong wave of enthusiasm and uptake for Eli Lilly and Novo Nordisk's blockbuster obesity medicines, the drugs have scored a strong endorsement from an independent U.S. cost watchdog. | ICER ...

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...

This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...

A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective ...